Biopharmaceuticals
-
Germany's Merck KGaA is investing $334 million to open a biopharmaceutical plant in Daejeon, South Korea, marking its largest life science investment in the Asia-Pacific region.
Germany's Merck KGaA has invested $334 million to open a biopharmaceutical plant in Daejeon, South Korea, marking its largest life science investment in the Asia-Pacific region. The 44,500-square-mete
-
China plans to include AI, biopharmaceuticals, and photovoltaic technologies in its export control list.
China's authorities on Friday proposed adding artificial intelligence, biopharmaceuticals, and photovoltaic technologies to its export control list to prevent the "improper proliferation" of related c
-
China aims for five innovative drugs with over $1 billion annual global sales by 2030
Beijing has set ambitious new five-year targets to boost its global presence, including at least five pharmaceutical products with annual global sales surpassing US$1 billion by 2030. Jefferies' head
-
ArriVent BioPharma's shares plummeted nearly 47% after its China-licensed cancer drug failed a late-stage trial.
Shares of U.S. biopharmaceutical company ArriVent BioPharma plummeted nearly 47% on Tuesday after it reported that firmonertinib, a cancer treatment licensed from Shanghai Allist Pharmaceuticals in Ch
-
Chinese Biopharma Stocks Rise as US Considers Allowing Most Drug Licensing Deals with Chinese Pharma Companies to Continue
On Monday, the Hang Seng Biotech Index rose over 5%, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up over 6%, Hutchmed up 3%, and Sino Biopharmaceutical up 8%. This follows re
-
Experts at Nordic Life Science Days suggest China's biopharma rise may be plateauing due to oversupply and rising prices
A panel of pharma representatives and analysts at the 2026 Nordic Life Science Days meeting in Stockholm noted that while licensing deals between US and Chinese biopharma companies hit record highs in
-
JonesTrading analysts initiated coverage on biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over the next year.
JonesTrading analyst Boris Peaker initiated coverage of biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over one year. Wall Street's
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Germany's Merck KGaA is investing $334 million to open a biopharmaceutical plant in Daejeon, South Korea, marking its largest life science investment in the Asia-Pacific region.
Germany's Merck KGaA has invested $334 million to open a biopharmaceutical plant in Daejeon, South Korea, marking its largest life science investment in the Asia-Pacific region. The 44,500-square-mete
-
China plans to include AI, biopharmaceuticals, and photovoltaic technologies in its export control list.
China's authorities on Friday proposed adding artificial intelligence, biopharmaceuticals, and photovoltaic technologies to its export control list to prevent the "improper proliferation" of related c
-
China aims for five innovative drugs with over $1 billion annual global sales by 2030
Beijing has set ambitious new five-year targets to boost its global presence, including at least five pharmaceutical products with annual global sales surpassing US$1 billion by 2030. Jefferies' head
-
ArriVent BioPharma's shares plummeted nearly 47% after its China-licensed cancer drug failed a late-stage trial.
Shares of U.S. biopharmaceutical company ArriVent BioPharma plummeted nearly 47% on Tuesday after it reported that firmonertinib, a cancer treatment licensed from Shanghai Allist Pharmaceuticals in Ch
-
Chinese Biopharma Stocks Rise as US Considers Allowing Most Drug Licensing Deals with Chinese Pharma Companies to Continue
On Monday, the Hang Seng Biotech Index rose over 5%, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up over 6%, Hutchmed up 3%, and Sino Biopharmaceutical up 8%. This follows re
-
Experts at Nordic Life Science Days suggest China's biopharma rise may be plateauing due to oversupply and rising prices
A panel of pharma representatives and analysts at the 2026 Nordic Life Science Days meeting in Stockholm noted that while licensing deals between US and Chinese biopharma companies hit record highs in
-
JonesTrading analysts initiated coverage on biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over the next year.
JonesTrading analyst Boris Peaker initiated coverage of biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over one year. Wall Street's
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
- No data
Biopharmaceuticals
24H Trending
-
1
CRO (Cronos) Price Pulls Back to $0.04135, Hitting Nearly 365-Day Low
-
2
The Taiwan Capitalization Weighted Stock Index (TAIEX) fell 3.81% from its previous close, currently standing at 38,665.32.
-
3
The Shanghai Composite Index fell 1.05% from its previous close, currently trading at 3,550.32.
-
4
CoinDesk: Nasdaq futures up nearly 2%; Anthropic indicative quotes briefly 24% higher
-
5
Financial Times: Anthropic Discloses Activation of Measures Under 'Responsible Scaling Policy'
-
6
CNBC: Musk says Anthropic intends to add 10 gigawatts of hashrate, and existing leasing agreements can be terminated by either party
-
7
Korean Media: Samsung's SmartThings Integrates ChatGPT Experimentally to Control Connected Home Devices
-
8
Laprophan has raised $223 million through an IPO on the Casablanca Stock Exchange, marking the largest fundraising deal by an African pharmaceutical company.
-
9
What is the total supply of Zilliqa? Introduction to ZIL Supply and Circulating Supply
-
10
Lookonchain: 4 wallets withdraw 13,408 ETH from FalconX, Galaxy Digital, and OKX
Markets Today
Recommended Reading

